This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Sept 2026 quarter: consolidated revenue up 41%, profit after tax up 62% year on year
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.5 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the quarter ended September 30, 2026, Titan Biotech reported unaudited consolidated revenue of Rs 76.46 crore, up 40.8% from Rs 54.29 crore a year earlier, and consolidated profit after tax of Rs 12.55 crore, up 61.6% from Rs 7.76 crore. Earnings before interest, tax, depreciation and amortisation rose to 19.6% of revenue from 17.2%. The limited review was clean; consolidated half-year operating cash flow was positive at Rs 12.88 crore.
Strong growth, wider margins and positive cash flow may support the share price, though results are unaudited and future performance is uncertain.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹135.6 Cr | ₹54.35 Cr | +149.5% |
| Operating profit | ₹24.33 Cr | ₹7.89 Cr | +208.2% |
| Profit after tax | ₹23.40 Cr | ₹7.76 Cr | +201.4% |
| EBITDA margin | 20.3% | 17.2% | +3.1 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.